Genmab A/S Return on Equity

Genmab A/S posts a ROE of 16.02%. That is above the Healthcare sector average of -100.59%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -100.59% is typical. Genmab A/S's 16.02% is higher that level. That is roughly 115.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Genmab A/S's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 16.02%; use YoY and peer views to separate noise from signal.

Context for GE9.F's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -100.59%), and (3) consistency with growth and profitability. This page covers the first two; Genmab A/S's other metric pages and overview cover the third.

Judging Genmab A/S against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 16.02% here, then scan peer and history charts to see if the gap is persistent.